ArticleJournal of cardiothoracic surgery2024
Appropriate use of vancomycin in a cardiac surgical unit.
Article in Journal of cardiothoracic surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exploring the effects of renal and cardiac functions on the pharmacokinetics of vancomycin in patients undergoing cardiac surgery: a population pharmacokinetic analysis.International journal of clinical pharmacy · 2026Article
- Utilization of prospective, pharmacist-driven restriction criteria to improve appropriateness of empiric intravenous vancomycin use.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAntibiotic resistance is a rapidly growing problem. Methicillin-resistant staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) are major worries, particularly in developing nations where cost-effectiveness is essential. Use of vancomycin must be restricted to prevent resistant to it. Examining the appropriateness rate of vancomycin use in light of the recommendations of the Infectious Disease Society of America (IDSA) in the cardiac surgery ward was the aim of this study. METHODOLOGY: This study was a retrospective analysis of the medical records of patients who received vancomycin over the previous year, from January 2023 to December 2023. The collected patient data included demographics, indications for vancomycin use, culture and sensitivity test results, concurrent antibiotic medications, vancomycin serum levels, and diagnoses. The appropriateness of vancomycin use was classified according to the recommendations of the Infectious Diseases Society of America (IDSA).
resultsA total of 294 patients received vancomycin. The appropriate use of vancomycin was significantly higher than its inappropriate use (p = 0.001). Approximately 41% (n = 120) of patients were administered vancomycin for treatment purposes, while the remainder received it empirically, but not as surgical prophylaxis. Appropriate use of vancomycin was observed in 89.1% (n = 262) of patients. However, there remained a notable rate of inappropriate vancomycin use (n = 32, 10.9%). The most common reason for inappropriate use was the continuation of vancomycin beyond 72 h without further evidence of a Gram-positive infection (n = 21, accounting for 65.6% of all inappropriate use).
conclusionsThe current study demonstrated that 89.1% of vancomycin use was appropriate, while approximately 10% was inappropriate, potentially contributing to vancomycin resistance. The majority of inappropriate use stems from frequent empirical prescribing, which requires further review and monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.